Literature DB >> 1977017

Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates.

J A Garson1, P W Tuke, M Makris, M Briggs, S J Machin, F E Preston, R S Tedder.   

Abstract

Sequential serum samples from previously untreated haemophiliacs in whom non-A, non-B hepatitis (NANBH) developed after they received factor VIII concentrate contaminated with hepatitis C virus (HCV) were tested by a commercial assay for the presence of antibodies to the C100 protein of HCV (anti-C100) and by "nested" PCR for the presence of HCV RNA sequences. Three temporal patterns of viraemia were observed: transient viraemia in acute resolving NANBH; viraemia lasting for several years in chronic NANBH; and intermittent viraemia in chronic NANBH, with an initial transient phase followed by recurrence after many months. In three of five cases the initial detection of serum HCV RNA was made before the onset of liver function test abnormality, many weeks or months before anti-C100 seroconversion. Diagnosis of acute HCV infection may therefore be possible much earlier by PCR than by existing serological techniques, but the timing of samples may be critical.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977017     DOI: 10.1016/0140-6736(90)92487-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  30 in total

1.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

2.  Comparative evaluation of two serologic typing methods for hepatitis C virus.

Authors:  A Cerino; A Cividini; M Asti; A Lanza; E Silini; M U Mondelli
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland.

Authors:  P J Conlon; J J Walshe; E G Smyth; E B McNamara; J Donohoe; M Carmody
Journal:  Ir J Med Sci       Date:  1993-04       Impact factor: 1.568

4.  Severe aplastic anemia associated with seronegative community-acquired hepatitis C virus infection.

Authors:  A Gruber; L Grillner; H Norder; L Magnius; M Björkholm
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

5.  Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing.

Authors:  K K Young; J J Archer; O Yokosuka; M Omata; R M Resnick
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Quantitative detection of hepatitis C virus genome in liver tissue and circulation by competitive reverse transcription-polymerase chain reaction.

Authors:  H Nakagawa; H Shimomura; T Hasui; H Tsuji; T Tsuji
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

7.  Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs.

Authors:  J P Allain; S H Dailey; Y Laurian; D S Vallari; A Rafowicz; S M Desai; S G Devare
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

8.  Association of hepatitis C virus in human sera with beta-lipoprotein.

Authors:  R Thomssen; S Bonk; C Propfe; K H Heermann; H G Köchel; A Uy
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

9.  Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus.

Authors:  H T Cuypers; D Bresters; I N Winkel; H W Reesink; A J Weiner; M Houghton; C L van der Poel; P N Lelie
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

10.  High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA.

Authors:  M Martell; J Gómez; J I Esteban; S Sauleda; J Quer; B Cabot; R Esteban; J Guardia
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.